United States: Pharmaceuticals Industry Guide

United States: Pharmaceuticals Industry Guide

Datamonitor's United States: Pharmaceuticals Industry Guide is an essential resource for top-level data and analysis covering the United States Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals

* Provides textual analysis of the industry's prospects

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Includes five-year forecasts for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals

Highlights

The US biotechnology market had total revenue of $71.2 billion in 2009, representing a compound annual growth rate (CAGR) of 8.2% for the period spanning 2005-2009.

The US generics market had total revenue of $69.3 billion in 2009, representing a compound annual growth rate (CAGR) of 10.3% for the period spanning 2005-2009.

The US OTC pharmaceuticals market generated total revenues of $27.5 billion in 2009, representing a compound annual growth rate (CAGR) of 3.4% for the period spanning 2005-2009.

The US pharmaceuticals market is expected to have total revenue of $292.8 billion in 2010, representing a compound annual growth rate (CAGR) of 2.9% for the period spanning 2006-2010.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research
TABLE OF CONTENTS
BIOTECHNOLOGY IN THE UNITED STATES 7
Market Overview 7
Market Value 9
Market Segmentation I 10
Market Segmentation II 11
Five Forces Analysis 12
Market Forecasts 19
GENERICS IN THE UNITED STATES 21
Market Overview 21
Market Value 23
Mark